Bristol-Myers Squibb to acquire Celgene in $74bn deal

American pharmaceutical company Bristol-Myers Squibb (BMS) has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

Big Pharma

Celgene sues Dr Reddy’s over Pomalyst generic

11 February 2021 Celgene has filed a lawsuit against Indian drugs manufacturer Dr Reddy’s Laboratories to halt its plan to produce and market generic versions of Pomalyst—Celgene’s multiple myeloma treatment.

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

Big Pharma

Celgene sues Dr Reddy’s over Pomalyst generic

More on this story

Americas

BMS to acquire Forbius in oncology expansion

27 August 2020 Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

Americas

BMS and Dr Reddy’s settle Revlimid suit with generics licence

22 September 2020 Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid.

Big Pharma

Celgene sues Dr Reddy’s over Pomalyst generic